SynthesisPloS one2025

Safety and efficacy of programmed cell death-1 inhibitors in relapsed immune-privileged site lymphoma: A systematic review and meta-analysis.

Ekdanai Uawithya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.